<DOC>
	<DOCNO>NCT00687193</DOCNO>
	<brief_summary>To evaluate dose-response relationship 5 dose CP-690,550 , compare placebo treatment sign symptoms patient active RA fail adequate trial therapy least 1 DMARD 12-week therapy .</brief_summary>
	<brief_title>Comparison Of 5 CP-690,550 Doses Vs . Placebo , For The Treatment Of Rheumatoid Arthritis In Japan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subjects must fail adequate trial therapy least 1 DMARD due lack efficacy toxicity . Current therapy DMARD</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Phase 2 monotherapy Japan</keyword>
</DOC>